Therapeutic strategies for the management of ulcerative colitis.
about
5-ASA Dose-Response: Maximizing Efficacy and Adherence.Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease.A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis.Impact of ileocecal resection and concomitant antibiotics on the microbiome of the murine jejunum and colon.Pros and cons of medical management of ulcerative colitis.Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia.Effects of curcumin on the apoptosis of cardiomyocytes and the expression of NF-κB, PPAR-γ and Bcl-2 in rats with myocardial infarction injury.Efficacy and safety of drugs for ulcerative colitis.The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.Practical application of anti-TNF therapy for luminal Crohn's disease.Novel topical therapies for distal colitis.Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article.Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkersUlcerative proctitis: an update on the pharmacotherapy and management.Common GI Drug Interactions in the Elderly.Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis.Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.Novel self-assembled mesalamine-sucralfate complexes: preparation, characterization, and formulation aspects.Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.Intestinal anti-inflammatory effects of goat whey on DNBS-induced colitis in mice.Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.Intracolonically administered adeno-associated virus-bone morphogenetic protein-7 ameliorates dextran sulphate sodium-induced acute colitis in rats.Long-term increase in serum cholesterol levels in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications.Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.Development and validation of the Nancy histological index for UC.Comparing histological activity indexes in UC.Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative ColitisShort-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis
P2860
Q33916329-7EE4E20F-0EC6-403F-A925-9529C1785851Q34037161-24EB6C5F-CF13-48BB-ABB5-877B80075574Q34533594-7E8AAB81-AD16-49C8-B1F9-1D583F36BA03Q34981695-441C2134-C20F-4669-B29F-0F54A07407A7Q35100726-85EA8C2A-A30F-441C-B8FE-8479251C5772Q36434492-0994E0E7-9D53-470D-94F8-3CB5B50F7F13Q37582188-7F98748D-9DD2-4FAD-BA31-A51021FCE41FQ37727232-32F8D5A5-32B0-43A2-8CBF-6CB7D1F67420Q37816246-9DCF15E9-3014-475D-BA06-64A556FCD599Q37845327-5FD5E51D-12F1-4813-9ED0-B3B0B4E1FCCBQ37876204-33E64602-A518-4CEF-80E0-7E2C5F93331FQ38056526-852EC20A-5B74-435A-BC5D-D6AD212A15CDQ38083084-2164383F-45FB-4685-8859-E4AE3F0FB29AQ38212456-CC8139E1-D5AD-4723-A6AE-F15AE7062EBBQ38230328-744F465C-EE1B-4075-AB12-2C0B6EB56240Q38357630-DFCDE029-A0B6-4C36-A5D8-2332E4ACDA8BQ38460376-BE32557F-7518-4ABD-BF02-8158F34799D0Q40315823-E3D99282-30D6-4985-BE90-90F68F6D3AB7Q41052913-E43B7849-9F87-44B2-B745-1AFC07474B2FQ42366229-67181579-4D85-41D1-828F-011E2FD65309Q43834227-523F1828-80A0-4F02-9416-E5959B71208CQ44073977-E16A0BF3-453D-493D-BE6F-022EE70FFDF7Q44478513-417D62A9-0E14-4FA8-BCCC-643F3260A0BFQ50070747-9428D16B-CEAF-4E21-866E-A4AE7B992D74Q50793198-F7D1BAD8-ED2D-4A18-AFD7-8EA7E37ECF82Q51051300-BF87A93D-10E9-4A66-B777-3D9115D792E7Q57265320-EFE97EEE-479B-4D0E-A4C6-626FAEC45565Q58694439-870CD712-5A37-4A5A-9DE8-79CC42F91025
P2860
Therapeutic strategies for the management of ulcerative colitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic strategies for the management of ulcerative colitis.
@en
Therapeutic strategies for the management of ulcerative colitis.
@nl
type
label
Therapeutic strategies for the management of ulcerative colitis.
@en
Therapeutic strategies for the management of ulcerative colitis.
@nl
prefLabel
Therapeutic strategies for the management of ulcerative colitis.
@en
Therapeutic strategies for the management of ulcerative colitis.
@nl
P2860
P356
P1476
Therapeutic strategies for the management of ulcerative colitis
@en
P2093
Michael A Kamm
P2860
P304
P356
10.1002/IBD.20797
P577
2009-06-01T00:00:00Z